


08-06-2002

A 10581-40

10/130525 Docket No. 14429



2 SHEET

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

531 Rec'd PCT 16 MAY 2002

102181328

Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
 Terje Espevik, Anders Sundan
 Additional name(s) of conveying party(ies) attached?
 Yes No

05/16/02

2. Name and address of receiving party(ies)
 Name: Leiv Eiriksson Nyfotek AS
 Address: Pirsenteret, N-7462 Trondheim, Norway
 City: _____ State: _____ Zip: _____
 Additional name(s) and address(es) attached?
 Yes No

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____
 Execution Date: 5/14/02

4. Application number(s) or patent number(s) 10/130525
 If this document is being filed together with a new application, the execution date of the application is 5/14/02

A. Patent Application No.(s)
 Additional numbers attached? Yes No

B. Patent No.(s)


5. Name and address of party to whom correspondence concerning document should be mailed:
 Name: Janet M. MacLeod
Dorsey & Whitney LLP
 Address: 250 Park Avenue.
 City: New York State: NY Zip: 10177

6. Total number of applications and patents involved: 1
 7. Total fee (37 CFR 3.41): \$ 40.00
 Enclosed
 Authorized to be charged to deposit account
 8. Deposit account number:
50-2054
 (Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature
To the best of my knowledge and belief, the foregoing instrumentation is true and correct and any attached copy is a true copy of the original document.
Janet M. MacLeod Janet M MacLeod May 16, 2002
 Name of Person Signing Signature Date

Total number of pages including cover sheet, attachments and document:



ASSIGNMENT

Attorney Docket No.: 14429

Page 1 of 2

First Named Inventor: Terje Espevik

Title: Antibody Against the Human Toll-Like Receptor-2 (TLR2) and Uses Thereof

WHEREAS, WE, TERJE ESPEVIK and ANDERS SUNDAN, citizens of Norway, whose post office addresses are Norwegian University of Science and Technology, Institute of Cancer Research and Molecular Biology, MTS, N-7489 Trondheim, Norway have invented certain new and useful improvements as described in an application entitled "Antibody Against the Human Toll-Like Receptor-2 (TLR2) and Uses Thereof" for Letters Patent of the United States, the application being filed herewith; and

WHEREAS, LEIV EIRIKSSON NYFOTEK AS, a corporation organized and existing under the laws of the State of Norway, and having offices at Pirsenteret, N-7462 Trondheim, Norway ("Assignee") is desirous of acquiring the entire right, title and interest in and to the invention, the application, and any and all Letters Patent or similar legal protection, foreign or domestic, to be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we transfer to Assignee, its successors and assigns, our entire right, title, and interest in and to the invention, the above-identified patent application, corresponding domestic applications (including divisionals, continuations, and continuations-in-part), corresponding foreign applications, all Letters Patent or similar legal protection issuing thereon, and all rights and benefits under any applicable treaty or convention; and we authorize the Commissioner of Patents and Trademarks of the United States or foreign equivalent thereof to issue the Letters Patent or similar legal protection to the Assignee.

We authorize the Assignee, its successors and assigns, or anyone it may properly designate, to apply for Letters Patent or similar legal protection, in its own name if desired, in any and all foreign countries.

We represent to the Assignee, its successors and assigns, that we have not and shall not execute any writing or do any act whatsoever conflicting with this Assignment. We, our executors or administrators, will at any time upon request, without additional consideration, but at the expense of the Assignee, its successors and assigns, execute such additional writings and do such additional acts as the Assignee, its successors and assigns, may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing the Letters Patent or similar legal protection on the invention in any and all countries.

Subscribed and executed at Trondheim on 14/5-2002
(Place) (Date)

Terje Espevik
Terje Espevik

Witness: Brun Hellegaard

Witness: Anders M. Thim

ASSIGNMENT

Attorney Docket No.: 14429

Page 2 of 2

First Named Inventor: Terje Espvik

Title: Antibody Against the Human Toll-Like Receptor-2 (TLR2) and Uses Thereof

Subscribed and executed at Tromsø on 05/14/02
(Place) (Date)

Anders Sunden
Anders Sunden

Witness: Bruno Melgaard

Witness: Anders M. Thim